These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22553056)

  • 1. Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621.
    Chandra G; Alexander V; Lee HW; Jeong LS
    Arch Pharm Res; 2012 Mar; 35(4):639-45. PubMed ID: 22553056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
    Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
    Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors.
    Aristegui SR; El-Murr MD; Golding BT; Griffin RJ; Hardcastle IR
    Org Lett; 2006 Dec; 8(26):5927-9. PubMed ID: 17165896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.
    Ihmaid S; Al-Rawi J; Bradley C; Angove MJ; Robertson MN; Clark RL
    Bioorg Med Chem; 2011 Jul; 19(13):3983-94. PubMed ID: 21664823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).
    Desage-El Murr M; Cano C; Golding BT; Hardcastle IR; Hummersome M; Frigerio M; Curtin NJ; Menear K; Richardson C; Smith GC; Griffin RJ
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4885-90. PubMed ID: 18678488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
    Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
    J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
    Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
    J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinase activity of DNA-PK is required to protect mammalian telomeres.
    Bailey SM; Brenneman MA; Halbrook J; Nickoloff JA; Ullrich RL; Goodwin EH
    DNA Repair (Amst); 2004 Mar; 3(3):225-33. PubMed ID: 15177038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
    Leahy JJ; Golding BT; Griffin RJ; Hardcastle IR; Richardson C; Rigoreau L; Smith GC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6083-7. PubMed ID: 15546735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.
    Clapham KM; Bardos J; Finlay MR; Golding BT; Griffen EJ; Griffin RJ; Hardcastle IR; Menear KA; Ting A; Turner P; Young GL; Cano C
    Bioorg Med Chem Lett; 2011 Feb; 21(3):966-70. PubMed ID: 21216595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).
    Cano C; Golding BT; Haggerty K; Hardcastle IR; Peacock M; Griffin RJ
    Org Biomol Chem; 2010 Apr; 8(8):1922-8. PubMed ID: 20449499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.
    Bowers S; Truong AP; Jeffrey Neitz R; Hom RK; Sealy JM; Probst GD; Quincy D; Peterson B; Chan W; Galemmo RA; Konradi AW; Sham HL; Tóth G; Pan H; Lin M; Yao N; Artis DR; Zhang H; Chen L; Dryer M; Samant B; Zmolek W; Wong K; Lorentzen C; Goldbach E; Tonn G; Quinn KP; Sauer JM; Wright S; Powell K; Ruslim L; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5521-7. PubMed ID: 21813278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
    Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactive competition between homologous recombination and non-homologous end joining.
    Allen C; Halbrook J; Nickoloff JA
    Mol Cancer Res; 2003 Oct; 1(12):913-20. PubMed ID: 14573792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
    J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
    Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
    Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.